EGFR and glioblastoma: More interestingly, the administration of Visudyne, an FDA-approved form of Verteporfin, in patients with suspected or known recurrent GBM showed its absorption in GBM tumor cells, suggesting the use of Verteporfin as a promising therapeutic agent for EGFR-amplified/mutant GBM.